138 related articles for article (PubMed ID: 33484159)
1. Radioiodine therapy reduces the frequency of circulating tumour cells in patients with differentiated thyroid cancer.
Schmidt M; Antke C; Mattes-György K; Hautzel H; Allelein S; Haase M; Dringenberg T; Schott M; Ehlers M
Clin Endocrinol (Oxf); 2021 Jun; 94(6):1004-1011. PubMed ID: 33484159
[TBL] [Abstract][Full Text] [Related]
2. "High-dose" radioiodine therapy in advanced differentiated thyroid carcinoma.
Menzel C; Grünwald F; Schomburg A; Palmedo H; Bender H; Späth G; Biersack HJ
J Nucl Med; 1996 Sep; 37(9):1496-503. PubMed ID: 8790201
[TBL] [Abstract][Full Text] [Related]
3. Low-dose radioiodine therapy for patients with intermediate- to high-risk differentiated thyroid cancer.
Abe K; Ishizaki U; Ono T; Horiuchi K; Kanaya K; Sakai S; Okamoto T
Ann Nucl Med; 2020 Feb; 34(2):144-151. PubMed ID: 31834567
[TBL] [Abstract][Full Text] [Related]
4. Differentiated thyroid cancer. Impact of adjuvant external radiotherapy in patients with perithyroidal tumor infiltration (stage pT4).
Farahati J; Reiners C; Stuschke M; Müller SP; Stüben G; Sauerwein W; Sack H
Cancer; 1996 Jan; 77(1):172-80. PubMed ID: 8630926
[TBL] [Abstract][Full Text] [Related]
5. Fractionated dosage of radioiodine for the ablation of low-risk differentiated thyroid cancer has no impact on survival.
Woliński K; Czepczyński R; Stangierski A; Trojanowski M; Rewaj-Łosyk M; Ziemnicka K; Bączyk M; Dyzmann-Sroka A; Ruchała M
Endokrynol Pol; 2018; 69(3):230-234. PubMed ID: 29504625
[TBL] [Abstract][Full Text] [Related]
6. Increased Numbers of Circulating Tumor Cells in Thyroid Cancer Patients.
Ehlers M; Allelein S; Schwarz F; Hautzel H; Kuebart A; Schmidt M; Haase M; Dringenberg T; Schott M
Horm Metab Res; 2018 Aug; 50(8):602-608. PubMed ID: 30081408
[TBL] [Abstract][Full Text] [Related]
7. FDG PET performed at thyroid remnant ablation has a higher predictive value for long-term survival of high-risk patients with well-differentiated thyroid cancer than radioiodine uptake.
Gaertner FC; Okamoto S; Shiga T; Ito YM; Uchiyama Y; Manabe O; Hattori N; Tamaki N
Clin Nucl Med; 2015 May; 40(5):378-83. PubMed ID: 25608175
[TBL] [Abstract][Full Text] [Related]
8. NIS and epithelial-mesenchymal transition marker expression of circulating tumor cells for predicting and monitoring the radioactive iodine-131 therapy effect in differentiated thyroid cancers.
Zheng L; Wang G; Guo W; Pan D; Xie L; He S; Luo C; Li H; Ran Y; Wu S; Liu F; Zhang X; Huang D
Mol Biol Rep; 2019 Aug; 46(4):4201-4212. PubMed ID: 31147861
[TBL] [Abstract][Full Text] [Related]
9. Use of recombinant human thyrotropin before radioiodine therapy in patients with advanced differentiated thyroid carcinoma.
Luster M; Lassmann M; Haenscheid H; Michalowski U; Incerti C; Reiners C
J Clin Endocrinol Metab; 2000 Oct; 85(10):3640-5. PubMed ID: 11061516
[TBL] [Abstract][Full Text] [Related]
10. Circulating Tumor Cells Correlate with Clinicopathological Features and Outcomes in Differentiated Thyroid Cancer.
Qiu ZL; Wei WJ; Sun ZK; Shen CT; Song HJ; Zhang XY; Zhang GQ; Chen XY; Luo QY
Cell Physiol Biochem; 2018; 48(2):718-730. PubMed ID: 30025398
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Survival Outcomes Following Postsurgical Radioactive Iodine Versus External Beam Radiation in Stage IV Differentiated Thyroid Carcinoma.
Yang Z; Flores J; Katz S; Nathan CA; Mehta V
Thyroid; 2017 Jul; 27(7):944-952. PubMed ID: 28446057
[TBL] [Abstract][Full Text] [Related]
12. Lacrimal System Obstruction After Radioiodine Therapy in Differentiated Thyroid Carcinomas: A Prospective Comparative Study.
da Fonseca FL; Yamanaka PK; Kato JM; Matayoshi S
Thyroid; 2016 Dec; 26(12):1761-1767. PubMed ID: 27565021
[TBL] [Abstract][Full Text] [Related]
13. RISK FACTORS FOR NONREMISSION AND PROGRESSION-FREE SURVIVAL AFTER I-131 THERAPY IN PATIENTS WITH LUNG METASTASIS FROM DIFFERENTIATED THYROID CANCER: A SINGLE-INSTITUTE, RETROSPECTIVE ANALYSIS IN SOUTHERN CHINA.
Chen P; Feng HJ; Ouyang W; Wu JQ; Wang J; Sun YG; Xian JL; Huang LH
Endocr Pract; 2016 Sep; 22(9):1048-56. PubMed ID: 27124694
[TBL] [Abstract][Full Text] [Related]
14. Clinical Significance of Circulating Tumor Cells (CTCs) and Survivin on Predicting Prognosis in Thyroid Cancer Patients.
Weng X; YangYang ; Cai Y
Dis Markers; 2022; 2022():5188006. PubMed ID: 35140820
[TBL] [Abstract][Full Text] [Related]
15. Is thyroid stunning clinically relevant? A retrospective analysis of 208 patients.
Etchebehere EC; Santos AO; Matos PS; Assumpção LV; Lima MC; Lima MC; Ward LS
Arq Bras Endocrinol Metabol; 2014 Apr; 58(3):292-300. PubMed ID: 24863093
[TBL] [Abstract][Full Text] [Related]
16. Radioiodine Uptake and Thyroglobulin-Guided Radioiodine Remnant Ablation in Patients with Differentiated Thyroid Cancer: A Prospective, Randomized, Open-Label, Controlled Trial.
Jin Y; Ruan M; Cheng L; Fu H; Liu M; Sheng S; Chen L
Thyroid; 2019 Jan; 29(1):101-110. PubMed ID: 30560716
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcome of low-risk differentiated thyroid cancer patients after radioiodine remnant ablation and recombinant human thyroid-stimulating hormone preparation.
Vianello F; Mazzarotto R; Mian C; Lora O; Saladini G; Servodio O; Basso M; Pennelli G; Pelizzo MR; Sotti G
Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):162-8. PubMed ID: 21411300
[TBL] [Abstract][Full Text] [Related]
18. Metastatic differentiated thyroid carcinoma: clinicopathological profile and outcome in an iodine deficient area.
Mishra A; Mishra SK; Agarwal A; Das BK; Agarwal G; Gambhir S
World J Surg; 2002 Feb; 26(2):153-7. PubMed ID: 11865341
[TBL] [Abstract][Full Text] [Related]
19. Salivary gland protection by amifostine in high-dose radioiodine treatment: results of a double-blind placebo-controlled study.
Bohuslavizki KH; Klutmann S; Brenner W; Mester J; Henze E; Clausen M
J Clin Oncol; 1998 Nov; 16(11):3542-9. PubMed ID: 9817273
[TBL] [Abstract][Full Text] [Related]
20. Fractionated dosage of radioiodine for the ablation of differentiated thyroid carcinoma.
Czepczyński R; Ziemnicka K; Baczyk M; Oleksa R; Ruchała M; Sowiński J
Thyroid; 2005 Nov; 15(11):1261-5. PubMed ID: 16356090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
